Dr. Reddy's Announces Launch of Montelukast Sodium Oral Granules

Dr. Reddy's Laboratories

announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair® (montelukast sodium) oral granules in the US market on September, 26, 2012, following the approval by the United States Food & Drug Administration (USFDA) of Dr.Reddy's ANDA for Montelukast Sodium Oral Granules. The Singulair® Oral Granules brand had U.S. sales of approximately $61 million for the most recent twelve months ending July 2012 according to IMS Health*. Dr. Reddy's Montelukast Sodium Oral Granules in 4 mg are available in unit dosage package of 30. DisclaimerThis press release includes forward-looking